An G, Jin J, Cai Z, Jing H, Fu C, He P, Xia Z, Liu R, Li L, Gai X, Zhang H, Zhu D, Luo X, Sun B, Xu H, Zhou L, Campagna M, Masterson TJ, Lau BW, Renaud T, Heuck C, Singh I, Vishwamitra D, Qiu L. Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study. haematol [Internet]. 2020Sep.10 [cited 2025Dec.5];. Available from: https://haematologica.org/article/view/12928